新型降脂药物PCSK9抑制剂在动脉粥样硬化心血管疾病的研究现状
Research status of new lipid-lowering drugs PCSK9 inhibitors in arteriosclerosis cardiovascular disease
马国文 1刘世昌 2王海亮 3姜文妍 4王学健4
作者信息
- 1. 山东第二医科大学药学院,山东 潍坊 261053;潍坊市人民医院,山东 潍坊 261041
- 2. 潍坊市精神卫生中心,山东 潍坊 261072
- 3. 潍坊市人民医院,山东 潍坊 261041
- 4. 山东第二医科大学药学院,山东 潍坊 261053
- 折叠
摘要
动脉粥样硬化是许多心血管疾病的早期病理改变,脂质代谢紊乱是动脉粥样硬化性心血管疾病(ASCVD)最重要的危险因素之一.前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型(PCSK9)是血脂调节的关键因子,可以通过与低密度脂蛋白受体(LDLR)结合,降解LDLR从而阻止低密度脂蛋白的清除,导致低密度脂蛋白胆固醇(LDL-C)水平升高,增加心血管疾病的风险.PCSK9 也参与炎症细胞因子的生成、内皮功能障碍和动脉粥样硬化斑块的形成.多项研究显示,PCSK9 是治疗ASCVD的一个有希望的新靶点.PCSK9 抑制剂是目前治疗高胆固醇血症的新型药物.本文就PCSK9 抑制剂在动脉粥样硬化中的作用及药物研究进展做一综述,为临床用药提供参考.
Abstract
Atherosclerosis is an early pathological change of many cardiovascular diseases.Lipid metabolism disorder is one of the most important risk factors of atherosclerotic cardiovascular disease(ASCVD).Proprotein convertase subtilisin/kexin type 9(PCSK9)is a key protein in lipid metabolism.It can bind to low-density lipoprotein receptor(LDLR)and degrade LDLR to prevent the clearance of low-density lipoprotein,resulting in increased low-density lipoprotein cholesterol(LDL-C)levels,and increasing risk of cardiovascular disease.PCSK9 is also involved in the production of inflammatory cytokines,endothelial dysfunction and the formation of atherosclerotic plaques.A number of studies have shown that PCSK9 is a promising new target for the treatment of ASCVD.PCSK9 inhibitors are currently a new type of drug for the treatment of hypercholesterolemia.This article reviewed the role of PCSK9 inhibitors in atherosclerosis and the research progress of drugs,so as to provide reference for clinical medication.
关键词
前蛋白转化酶枯草杆菌蛋白酶/kexin9型抑制剂/动脉粥样硬化/人前蛋白转化酶枯草溶菌素9/动脉粥样硬化性心血管疾病/胆固醇/低密度脂蛋白胆固醇Key words
Proprotein convertase subtilisin/kexin type 9 inhibitors/Atherosclerosis/Human proprotein convertase subtilisin/kexin type 9 inhibitor/ASCVD/Cholesterol/Low-density lipoprotein cholesterol引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据